DBTX Key Statistics, Chart & Performance
The current stock price of DBTX is 4.91 USD. In the past month the price decreased by -4.1%. In the past year, price increased by 28.53%.
DBTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DBTX. When comparing the yearly performance of all stocks, DBTX is one of the better performing stocks in the market, outperforming 91.28% of all stocks.
DBTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DBTX. Both the profitability and financial health of DBTX have multiple concerns.
DBTX Financial Highlights
Over the last trailing twelve months DBTX reported a non-GAAP Earnings per Share(EPS) of -2.53. The EPS decreased by -9.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DBTX Forecast & Estimates
10 analysts have analysed DBTX and the average price target is 7.78 USD. This implies a price increase of 58.4% is expected in the next year compared to the current price of 4.91.
For the next year, analysts expect an EPS growth of -15% and a revenue growth -100% for DBTX
DBTX Ownership
About DBTX
Company Profile
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Company Info
DECIBEL THERAPEUTICS INC
1325 Boylston Street, Suite 500
Boston MASSACHUSETTS 02215 US
CEO: Laurence Reid
Employees: 68
Phone: 16173708701.0
DECIBEL THERAPEUTICS INC / DBTX FAQ
Can you describe the business of DECIBEL THERAPEUTICS INC?
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 68 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
What is the stock price of DECIBEL THERAPEUTICS INC today?
The current stock price of DBTX is 4.91 USD. The price decreased by -0.81% in the last trading session.
What is the dividend status of DECIBEL THERAPEUTICS INC?
DBTX does not pay a dividend.
How is the ChartMill rating for DECIBEL THERAPEUTICS INC?
DBTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of DECIBEL THERAPEUTICS INC (DBTX) based on its PE ratio?
DECIBEL THERAPEUTICS INC (DBTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.53).
Can you provide the number of employees for DECIBEL THERAPEUTICS INC?
DECIBEL THERAPEUTICS INC (DBTX) currently has 68 employees.
When does DECIBEL THERAPEUTICS INC (DBTX) report earnings?
DECIBEL THERAPEUTICS INC (DBTX) will report earnings on 2023-11-07, after the market close.